Reports from National University, Medical Department add new data to research in proteinuria

Return to Proteomics Alert Section

March 16th, 2009

   2009 MAR 16 -- According to recent research from Singapore, Singapore, "Although sirolimus (SRL) use in renal allograft recipients (RTX) is associated with improved renal function, proteinuria develops in a significant proportion. 48 SRL-treated RTX were evaluated for development of proteinuria and stratified by level of proteinuria after SRL therapy. The Proteinuria Group (n = 25, 52.1%) had new-onset proteinuria or > 25% increase in proteinuria following SRL conversion; the Nonproteinuria Group had stable proteinuria < 0.5 g/day throughout."

   "There was a higher proportion of male RTX and female donors to male recipients in the Proteinuria Group, (24% vs. 10%, P = 0.008). Calcineurin inhibitor- and statin usage were significantly higher in the Nonproteinuria Group (8% vs. 17%, P = 0.046; 28% vs. 83%, P< 0.001 respectively) whereas biopsy-proven acute rejection was higher in the Proteinuria Group (68% vs. 33%, P = 0.037). SDS-PAGE analysis of urine from 23 RTX in the Proteinuria Group demonstrated glomerular proteinuria in 100% and tubular proteinuria in 87%. While male gender and gender mismatch may impact on glomerular proteinuria through inadequate nephron dose and subsequent hyperfiltration, concurrent cyclosporine use may mitigate the development of proteinuria in SRL-treated patients, through afferent arteriolar vasoconstriction. Glomerular injury occurring following acute rejection may further contribute to glomerular proteinuria," wrote A. Liew and colleagues, National University, Medical Department.

   The researchers concluded: "Statins, through their anti-inflammatory and anti-fibrotic effects, may protect against development of proteinuria."

   Liew and colleagues published their study in Transplant International (Factors associated with proteinuria in renal transplant recipients treated with sirolimus. Transplant International, 2009;22(3):313-322).

   For additional information, contact A. Vathsala, Singapore National University, Yong Loo Lin School Medical, Dept. of Medical, Division Nephrology, 5 Lower Kent Ridge Rd., Singapore 119074, Singapore.

   Publisher contact information for the journal Transplant International is: Wiley-Blackwell Publishing, Inc., Commerce Place, 350 Main St., Malden 02148, MA, USA.

   Keywords: Singapore, Singapore, Cyclosporine, Drugs, Kidney Transplant, Nephrology, Organ Transplant, Pharmaceuticals, Proteinuria, Renal Allograft, Renal Function, Renal Transplant, Sirolimus, Therapy, Transplantation, Treatment, National University, Medical Department.

   This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.

Return to Proteomics Alert Section